Drug Profile
Research programme: respiratory tract disorder therapeutics - Zai Lab
Alternative Names: ZL 2101Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator Sanofi
- Developer ZAI Lab
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Chronic obstructive pulmonary disease in China (unspecified route) (ZAI Lab pipeline, April 2023)
- 25 Apr 2023 Discontinued - Preclinical for Idiopathic pulmonary fibrosis in China (unspecified route) (ZAI Lab pipeline, April 2023)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in China